Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials

Monique C Minnema, Xiang Yin, Ruthanna Davi, Sam Keeping, Julie E Park, Taha Itani, Tsveta Hadjivassileva, Jean-Gabriel Castaigne, Rita Damico Khalid, Lang Zhou, James J Wu, Bijal D Shah

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 CAR T-cell therapy approved in the USA and European Union (EU) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL; aged ≥26 years in EU). Here, outcomes for patients with R/R B-ALL aged ≥26 years in ZUMA-3 treated with brexu-cel were compared with historical standard-of-care (SOC) therapy. After median follow-up of 26.8 months, the overall complete remission (CR) rate among patients treated with brexu-cel in Phase 2 ( N = 43) was 72% and median overall survival (OS) was 25.4 months (95% CI, 15.9-NE). Median OS was improved in Phase 2 patients versus matched historical SOC-treated patients. Compared with aggregate historical trial data, Phase 1 and 2 patients had improved OS versus blinatumomab, inotuzumab, and chemotherapy in a matching-adjusted indirect comparison (MAIC) study. These data demonstrate clinical benefit of brexu-cel relative to SOC in patients ≥26 years with R/R B-ALL.

Original languageEnglish
Pages (from-to)1438-1447
Number of pages10
JournalLeukemia & lymphoma
Volume65
Issue number10
Early online date24 May 2024
DOIs
Publication statusPublished - Oct 2024

Keywords

  • B-cell acute lymphoblastic leukemia
  • brexucabtagene autoleucel
  • CAR T-cell therapy
  • CD-19
  • SCHOLAR-3
  • ZUMA-3

Fingerprint

Dive into the research topics of 'Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials'. Together they form a unique fingerprint.

Cite this